Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease

Abstract

BACKGROUND The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time. METHODS We conducted a randomized, placebo-controlled trial of valganciclovir therapy in neonates with symptomatic congenital CMV disease, comparing 6 months of therapy with 6 weeks of therapy. The primary end point was the change in hearing in the better ear (“best-ear” hearing) from baseline to 6 months. Secondary end points included the change in hearing from baseline to follow-up at 12 and 24 months and neurodevelopmental outcomes, with each end point adjusted for central nervous system involvement at baseline. RESULTS A total of 96 neonates underwent randomization, of whom 86 had follow-up data at 6 months that could be evaluated. Best-ear hearing at 6 months was similar in the 6-month group and the 6-week group (2 and 3 participants, respectively, had improvement; 36 and 37 had no change; and 5 and 3 had worsening; P = 0.41). Total-ear hearing (hearing in one or both ears that could be evaluated) was more likely to be improved or to remain normal at 12 months in the 6-month group than in the 6-week group (73% vs. 57%, P = 0.01). The benefit in total-ear hearing was maintained at 24 months (77% vs. 64%, P = 0.04). At 24 months, the 6-month group, as compared with the 6-week group, had better neurodevelopmental scores on the Bayley Scales of Infant and Toddler Development, third edition, on the language-composite component (P = 0.004) and on the receptive-communication scale (P = 0.003). Grade 3 or 4 neutropenia occurred in 19% of the participants during the first 6 weeks. During the next 4.5 months of the study, grade 3 or 4 neutropenia occurred in 21% of the participants in the 6-month group and in 27% of those in the 6-week group (P = 0.64). CONCLUSIONS Treating symptomatic congenital CMV disease with valganciclovir for 6 months, as compared with 6 weeks, did not improve hearing in the short term but appeared to improve hearing and developmental outcomes modestly in the longer term. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT00466817.)

Cytomegalovirus (CMV) Infection Causes Degeneration of Cochlear Vasculature and Hearing Loss in a Mouse Model

“…If the initial target of a viral infection is the stria vascularis, then with early detection and diagnosis, perhaps, some treatment for recovery is possible. This notion that CMV infection involves an initial phase of strial damage and a loss of EP is consistent with reports that early intervention with anti-viral agents such as gan/ valganciclovir can improve hearing outcomes (e.g., Kimberlin et al 2003Kimberlin et al , 2015Bilavsky et al 2016).…”

Breast Milk-Transmitted Cytomegalovirus Infection in Preterm Infants

“…At present, guidelines for the treatment of congenital CMV infection have been suggested 42) . But in cases of perinatally or postnatally acquired symptomatic CMV infection, there is no consensus on the management, although the use of antiviral treatment in severe and symptomatic cases have been reported 39,40) .…”

Diagnóstico etiológico de la sordera infantil: Recomendaciones CODEPEH 2015

“…Está en discusión la recomendación de realizar cribado universal de la infección por CMV en orina (más exacto) o saliva (más factible) (Kadambari et al, 2015) (Barkai et al, 2014) (Cannon et al, 2014) (Botet et al, 2014), basándose en la elevada prevalencia de la infección y la posibilidad de mejorar el pronóstico con un manejo y tratamiento adecuado (Kimberlin et al, 2015).…”